ClinicalTrials.gg
Status unknownNCT05449704Updated Jul 8, 2022

Pharmacokinetics and Safety Profiles After Administration of DA-5218 and Co-administration of DA-5218-R1, DA-5218-R2 and DA-5218-R3 in Healthy Adult Volunteers

A Phase 1 interventional study of DA-5218 and DA-5218-R1 + DA-5218-R2 + DA-5218-R3 in Healthy, sponsored by Dong-A ST Co., Ltd.. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-07-08.

Sponsored by Dong-A ST Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jul 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

Pharmacokinetics and safety Profiles after administration of DA-5218 and co-administration of DA-5218-R1, DA-5218-R2 and DA-5218-R3 in healthy adult volunteers

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Dong-A ST Co., Ltd. is the lead sponsor of 122 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers
  • between 18 and 30 kg/m2
  • Body weight: Male≥50kg, Female≥45kg
  • Subjects who have signed an themselves after receiving detailed explanation about clinical study

Exclusion criteria

Exclusion Criteria:

  • Subjects with allergy or drug
  • Subjects with medical history
  • Subjects with history of drug abuse or addicted
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Sequence A

    Drug: DA-5218 · Drug: DA-5218-R1 + DA-5218-R2 + DA-5218-R3

  • Experimental
    Sequence B

    Drug: DA-5218 · Drug: DA-5218-R1 + DA-5218-R2 + DA-5218-R3

Interventions

  • DrugDA-5218

    single dose administration (DA-5218 one tablet once a day)

  • DrugDA-5218-R1 + DA-5218-R2 + DA-5218-R3

    single dose administration (DA-5218-R1 one tablet once a day + DA-5218-R2 one tablet once a day + DA-5218-R3 one tablet once a day)

06

What researchers measure

Primary outcomes

  1. AUCt

    area under the curve

    Time frame: pre-dose~72 hours post-dose

  2. Cmax

    maximum plasma concentration

    Time frame: pre-dose~72 hours post-dose

07

Study locations

1 site
  • Bumin Hospital
    Seoul, 07590, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2022; primary completion for Sep 2022, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2022
First posted
Jul 8, 2022
StartEst.
Jul 8, 2022
Primary completionEst.
Sep 3, 2022
CompletionEst.
Sep 7, 2022
Last update
Jul 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05449704
Responsible party
Sponsor
First posted
Jul 8, 2022
Start date
Jul 8, 2022 (estimated)
Primary completion
Sep 3, 2022 (estimated)
Completion
Sep 7, 2022 (estimated)
Last update
Jul 8, 2022

Study contacts

JiHyun Sung
Contact
jhsung@donga.co.kr
+82-2-920-8369

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion